Adding saxagliptin to metformin instead of increasing the dose of metformin results in significant improvement in levels of hemoglobin 1c (HbA1c), fasting plasma glucose, and postprandial glucose in patients with type 2 diabetes with inadequate glycemic control despite being on a stable dose of metformin, according to the results of a randomized open-label study.